Puberty Blockers for Gender Dysphoria

"The age range for participants in this study is between 9 and 14 years old."

"Affirmative, information on clinicaltrials.gov declares that this medical experiment is actively enrolling participants. It was first posted in September 15th 2020 and most recently updated on the 8th of September 2022. The study requires 80 volunteers from two separate locations."

"The primary objective of this research project, which will be monitored for a period extending from the Baseline to 12 months, is assessing bone marrow adiposity through MRI. The secondary outcomes include measuring Lumbar spine BMD Z-score using DXA and Hip bone mineral density (g/cm2) as well as Volumetric bone mineral density (vBMD) via pQCT scans acquired at 3%, 38%, and 66% of tibial length proximal to the distal growth plate."

"This clinical trial, initially published on September 15th 2020, is actively seeking participants. Data hosted on clinicaltrials.gov was last updated on September 8th 2022."

"This trial is seeking 80 participants aged between 9 and 14 who are currently undergoing puberty. Eligible candidates must have visited either the BCH Transgender Clinic or CCHMC Transgender Clinic, be within 6 weeks of initiation pubertal blockade treatment (i.e., using drugs such as Lupron or Vantas), willingly give informed consent/assent (with parent/guardian permission necessary if applicable) , display a Tanner Stage II/III, fit into the age bracket associated with their assigned gender at birth (AMAB: 9-14 years old; AFAB: 9-13 years old), match controls in terms of race/"